Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T‐cell Lymphoma | Zendy

Houot Roch | Zendy; Poeschel Viola | Zendy; Altmann Bettina | Zendy; Angel Stephanie | Zendy; Thurner Lorenz | Zendy; Illmer Thomas | Zendy; Andre Marc | Zendy; Dreyling Martin | Zendy; Maisonneuve Hervé | Zendy; Tilly Hervé | Zendy; Mayer Stephanie | Zendy; Casasnovas Olivier | Zendy; Le Gouill Steven | Zendy; Offner Fritz | Zendy; Cartron Guillaume | Zendy; Kerkhoff Andrea | Zendy; Weber Thomas | Zendy; Hoffmann Joerg | Zendy; Ziepert Marita | Zendy; Klapper Wolfram | Zendy; Itti Emmanuel | Zendy; Hellwig Dirk | Zendy; Natchkebia Giorgi | Zendy; Leval Laurence | Zendy; Rosenwald Andreas | Zendy; Haioun Corinne | Zendy; Dercle Laurent | Zendy; Gaulard Philippe | Zendy; Held Gerhard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T‐cell Lymphoma

Author(s) -

Houot Roch,

Poeschel Viola,

Altmann Bettina,

Angel Stephanie,

Thurner Lorenz,

Illmer Thomas,

Andre Marc,

Dreyling Martin,

Maisonneuve Hervé,

Tilly Hervé,

Mayer Stephanie,

Casasnovas Olivier,

Le Gouill Steven,

Offner Fritz,

Cartron Guillaume,

Kerkhoff Andrea,

Weber Thomas,

Hoffmann Joerg,

Ziepert Marita,

Klapper Wolfram,

Itti Emmanuel,

Hellwig Dirk,

Natchkebia Giorgi,

Leval Laurence,

Rosenwald Andreas,

Haioun Corinne,

Dercle Laurent,

Gaulard Philippe,

Held Gerhard

Publication year - 2022

Publication title -

hemasphere

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.677

H-Index - 11

ISSN - 2572-9241

DOI - 10.1097/hs9.0000000000000672

Subject(s) - medicine , oxaliplatin , nivolumab , gemcitabine , regimen , oncology , carboplatin , refractory (planetary science) , population , chemotherapy regimen , lymphoma , chemotherapy , rituximab , cancer , immunotherapy , cisplatin , colorectal cancer , physics , environmental health , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore